- Exchange: OTC US
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Drug Delivery Systems
Snapshot for Pharmos Corp (PARS)
| Open: | 0.0360 | Day's Range: | 0.0360 - 0.0450 | Volume: | 41,410 |
|---|---|---|---|---|---|
| Previous Close: | 0.0370 | 52wk Range: | 0.0200 - 0.0900 | 1-Yr Rtn: | -47.50% |
Key Statistics for PARS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(-) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (ttm) | -0.0400 |
| Est. EPS | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 2.53 |
| Shares Outstanding (M) | 60.17 |
| 30 Day Average Volume | 26,543 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | - |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for PARS
No data available
Company Profile & Key Executives for PARS
Pharmos Corporation is a bio-pharmaceutical company that discovers and develops new drugs to treat a range of neuroinflammatory disorders. The company has a portfolio of drug candidates under development. Pharmos's main product, dexanabinol, is a synthetic non-psychotropic cannabinoid currently in late stage clinical development for the treatment of traumatic brain injury (TBI).
| Robert F JohnstonChairman | Eric W FangmannActing President/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
PARS News
-
Industry News
No stories found
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page